Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Condor Production Exceeds 16,900 boe/d as K-42 Delivers Stronger Than Expected Results (GlobeNewswire EN) +++ CONDOR ENERGIES Aktie -4,15%

Q32 BIO Aktie

 >Q32 BIO Aktienkurs 
16.99 EUR    +73.0%    (TradegateBSX)
Ask: 17.02 EUR / 500 Stück
Bid: 16.67 EUR / 500 Stück
Tagesumsatz: 8576 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Q32 BIO Aktie über LYNX handeln
>Q32 BIO Performance
1 Woche: -8,6%
1 Monat: -4,5%
3 Monate: +154,3%
6 Monate: +236,3%
1 Jahr: +263,2%
laufendes Jahr: +290,3%
>Q32 BIO Aktie
Name:  Q32 BIO INC. O.N.
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US7469641051 / A4ZZ0Z
Symbol/ Ticker:  DB0 (Frankfurt) / QTTB (NASDAQ)
Kürzel:  FRA:DB0, ETR:DB0, DB0:GR, NASDAQ:QTTB
Index:  -
Webseite:  https://www.q32bio.com/
Profil:  Q32 Bio Inc. is a clinical-stage biotechnology company developing biologic therapeutics that target potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. Its primary focus is on be..
>Volltext..
Marktkapitalisierung:  232.54 Mio. EUR
Unternehmenswert:  200.04 Mio. EUR
Umsatz:  47.07 Mio. EUR
EBITDA:  19.07 Mio. EUR
Nettogewinn:  29.12 Mio. EUR
Gewinn je Aktie:  2.34 EUR
Schulden:  11.95 Mio. EUR
Liquide Mittel:  44.46 Mio. EUR
Operativer Cashflow:  -24 Mio. EUR
Bargeldquote:  4.76
Umsatzwachstum:  -
Gewinnwachstum:  -
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  Q32 BIO
Letzte Datenerhebung:  13.07.26
>Q32 BIO Kennzahlen
Aktien/ Unternehmen:
Aktien: 23.68 Mio. St.
Frei handelbar: 40.13%
Leerverk. Aktien: 3.99%
Rückkaufquote: -3.9%
Mitarbeiter: 24
Umsatz/Mitarb.: 1.96 Mio. EUR
Analysten:
Analystenrating: Strong buy
Kursziel: 20.05%
Bewertung:
KGV: 4.46
KGV lG: -
KUV: 3.39
KBV: 3.75
PEG-Ratio: -
EV/EBITDA: 10.49
Rentabilität:
Bruttomarge: 99.33%
Gewinnmarge: 61.86%
Operative Marge: 39.84%
Managementeffizenz:
Gesamtkaprendite: 46.58%
Eigenkaprendite: 157.18%
>Q32 BIO Peer Group
Gesundheit, Antikörper- Behandlung, Autoimmunerkrankungen
 
13.07.26 - 13:18
 Aktie von Q32 Bio schießt nach positiven Studiendaten zu Haarausfall um 60 % in die Höhe (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
10.07.26 - 22:09
 Q32 Bio to Report 36-Week Topline Results from Part B of SIGNAL-AA Clinical Trial of Bempikibart in Alopecia Areata on July 13, 2026 (PR Newswire)
 
-- Conference call to be held Monday, July 13th at 8:00 a.m. E.T. -- WALTHAM, Mass., July 10, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata ("AA") and other autoimmune and......
08.06.26 - 17:18
 Q32 Bio: Aktie bricht nach Kapitalmaßnahmen und Verwässerungsdruck ein (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
02.06.26 - 10:01
 Insiderhandel: Aufsichtsrat kauft Aktien von Q32 Bio im Wert von 15000000 USD (Insiderkauf)
 
Xu, Diyong - Aufsichtsrat - Tag der Transaktion: 2026-05-28...
29.05.26 - 16:24
 Why Is Q32 Bio Stock Gaining Friday? (Benzinga)
 
Q32 Bio ($QTTB) jumps in premarket trading after securing a $55M private placement to fund its autoimmune pipeline. Read more. Importance Rank:  1 read more...
28.05.26 - 10:24
 Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX (RTTNews)
 
Today's Top Gainers list features Q32 Bio, which announced a $55 million private placement financing; Soligenix, which is exploring the suitability of its ThermoVax platform to fight the Bundibugyo strain of Ebola virus; P3 Health Partners, which recently reported strong quarterly results; and Editas Medicine, which is advancing its pipeline....
27.05.26 - 15:01
 Q32 Bio: Aktie springt nach 55-Millionen-Dollar-Privatplatzierung (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
27.05.26 - 14:51
 Q32 Bio announces $55M private placement (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
27.05.26 - 14:01
 Q32 Bio Announces $55 Million Private Placement Financing (PR Newswire)
 
WALTHAM, Mass., May 27, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio" or "Company"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that it has entered......
26.05.26 - 17:30
 Wall Street Analysts Think Q32 Bio (QTTB) Could Surge 145.69%: Read This Before Placing a Bet (Zacks)
 
The average of price targets set by Wall Street analysts indicates a potential upside of 145.7% in Q32 Bio (QTTB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....
22.05.26 - 16:03
 This Q32 Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday (Benzinga)
 
Analysts change outlook on top names. Check out ratings page for upgrades, downgrades, and initiations. Importance Rank:  1 read more...
08.05.26 - 17:30
 Wall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here′s is How to Trade (Zacks)
 
The consensus price target hints at a 163.4% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....
05.05.26 - 13:36
 Q32 Bio GAAP EPS of -$0.54 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
05.05.26 - 13:01
 Q32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
 
-- Bempikibart 36-week topline data readout from Part B of SIGNAL-AA Phase 2a clinical trial on-track for mid-2026 -- -- First patient dosed in SIGNAL-AA Part B open-label extension (OLE) -- -- Completed $10.5 million registered direct offering (RDO) -- -- Cash and cash equivalents of $50.......
30.04.26 - 23:00
 Q32 Bio Gears Up to Report Q1 Earnings: What′s in the Cards? (Zacks)
 
QTTB heads into Q1 earnings with investors eyeing bempikibart updates, as the SIGNAL-AA study progresses with data due in mid-2026....
08.04.26 - 13:01
 Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference (PR Newswire)
 
WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced that management will......
30.03.26 - 17:30
 Does Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect? (Zacks)
 
The consensus price target hints at a 97.7% upside potential for Q32 Bio (QTTB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term....
19.03.26 - 18:45
 Q32 Bio (QTTB) Upgraded to Strong Buy: Here′s What You Should Know (Zacks)
 
Q32 Bio (QTTB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....
13.03.26 - 16:30
 Wall Street Analysts See a 103.55% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High? (Zacks)
 
The mean of analysts' price targets for Q32 Bio (QTTB) points to a 103.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....
10.03.26 - 12:00
 Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update (PR Newswire)
 
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Completed $10.5 million registered direct offering (RDO) -- -- Completed asset sale of Phase 2......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Die Absicht eines Christen, der ein Streitgespräch über die Glaubenswahrheiten führt, muß nicht darauf zielen, den Glauben zu beweisen, sondern den Glauben zu verteidigen. - Hl. Thomas von Aquin
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!